GENERAL NUTRACEUTICAL TECHNOLOGY LLC
Elmsford, NY · Biotech · Private
Xanthopurpurin (XPP), a small molecule anthraquinone compound that suppresses food allergen-specific IgE to treat food allergies
- Grants
- $3.5M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · IgE Suppressing Berberine Nanomedicine for Treatment of Food Allergies | $225,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · IgE Suppressing Berberine Nanomedicine for Treatment of Food Allergies | $920,225 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · IgE Suppressing Berberine Nanomedicine for Treatment of Food Allergies | $920,225 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · IgE-suppressing small molecule compound Xanthopurpurin analog for multiple food allergies | $289,622 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · IgE-suppressing small molecule compound Xanthopurpurin analog for multiple food allergies | $289,622 | |
| Federal grant | Department of Health and Human Services · Phase II · IgE Suppressing Berberine Nanomedicine for Treatment of Food Allergies | $894,193 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1644 | MIDI, INC. | — | — |
| 1645 | CANCER TARGETED TECHNOLOGY, LLC | — | — |
| 1646 | IMMUNARTES LLC | — | — |
| 1647 | GENERAL NUTRACEUTICAL TECHNOLOGY LLC | — | — |
| 1648 | Boston Immune Technologies And Therapeutics Inc. | — | — |
| 1649 | Respana Therapeutics, Inc | — | — |
| 1650 | Seawolf Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Compositions And Methods For Treating Eczemaapplication
- Compositions And Methods For Treating Eczemaapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.